Showing 791-800 of 2254 results for "".
- Muscular Dystrophy Association Announces the Start of 30 Days of Strength Campaignhttps://practicalneurology.com/news/mda-announces-the-start-of-30-days-of-strength-campaign/2470289/The Muscular Dystrophy Association (MDA) has announced the start of its 30 Days of Strength campaign for September, which is National Muscular Dystrophy Awareness Month. Throughout the month, the MDA will collaborate with influencers and community leaders, including Nyheim Hines, running back for
- VA Will Cover Lecanemab for Alzheimer Diseasehttps://practicalneurology.com/news/va-will-cover-lecanemab-for-alzheimer-disease/2470141/The Veterans Health Administration (VHA)—the division of the US D
- Ribitol Decreased Muscle Breakdown and Improved Function in Limb-Girdle Muscular Dystrophyhttps://practicalneurology.com/news/ribitol-decreased-muscle-breakdown-and-improved-function-in-limb-girdle-muscular-dystrophy/2470048/In a phase 2 study, individuals treated with ribitol (BBP-418; BridgeBio Pharma, Palo Alto, CA) for limb girdle muscular dystrophy type 2i (LGMD2i) for 12 months had a mean 75% reduction in creatine kinase (CK) levels—a marker of muscle degeneration. A mean 0.95-point improvement from basel
- Price of Aducanumab Treatment for Early Alzheimer Disease Cut in Halfhttps://practicalneurology.com/news/price-of-aducanumab-treatment-for-early-alzheimer-disease-cut-in-half/2469783/The price of the first potentially disease-modifying treatment for Alzheimer disease (AD), aducanumab (Aduhelm; Biogen, Cambridge, MA and Eisai, Woodcliff Lake, NJ), has been reduced by 50%—from $56,000 to $28,000 annually. Aducanumab was approved via the accelerated pathway for treatment o
- Advances in Preventive Treatment of Migraine Continuehttps://practicalneurology.com/news/advances-in-preventive-treatment-of-migraine-continue/2469756/At the Scottsdale Headache Symposium, the latest pharmacologic treatments for prevention of episodic migraine were reviewed. The focus remained on pharmacologic therapies that inhibit or block the effects of calcitonin gene-related peptide (CGRP) and its receptor—the first preventive treatm
- Muscular Dystrophy Association and Magic Wheelchair Launch 2022 Halloween Costume Competition to Raise Neuromuscular Disease Awarenesshttps://practicalneurology.com/news/muscular-dystrophy-association-and-magic-wheelchair-launch-2022-halloween-costume-competition-to-raise-neuromuscular-disease-awareness/2469729/The Muscular Dystrophy Association (MDA) and Magic Wheelchair have launched a Instagram competition to win a Magic Wheelchair Halloween costume in 2022. To enter, participants with neuromuscular diseases need to follow@MDAorg and @MagicWheelchair on Instagram and comment with a purple heart on al
- Sudden Unexpected Death in Epilepsy More Prevalent in Black and Multiracial Childrenhttps://practicalneurology.com/news/sudden-unexpected-death-in-epilepsy-more-prevalent-in-black-and-multiracial-children/2469452/Findings from a large national registry presented virtually at the American Epilepsy Society AES2020 revealed that sudden unexpected death in epilepsy (SUDEP) is more common in infants and children than previously reported. The population-based study—the first of its kind in the US—fo
- Vascular Health and Treating Migrainehttps://practicalneurology.com/news/vascular-health-and-treating-migraine/2469440/As new migraine treatments have become available that do not have cardiovascular contraindications, many questions have arisen regarding whether a new therapy—lasmiditan—is truly safe for those with cardiovascular risk. These important considerations for the 12% of peo
- Muscular Dystrophy Association Launches Data Reporting and Visualization Platform for Neuromuscular Diseasehttps://practicalneurology.com/news/muscular-dystrophy-association-launches-data-reporting-and-visualization-platform-for-neuromuscular-disease/2469411/The Muscular Dystrophy Association (MDA) has announced the availability of its new data sharing platform, the neuromuscular observational research (MOVR) visualization and reporting platform (VRP). MOVR-VRP represents a milestone in advancing neuromuscular disease research and improving patient c
- FDA Approves Expanded use of Pitolisant for Treatment of Cataplexy in Adults With Narcolepsyhttps://practicalneurology.com/news/fda-approves-expanded-use-of-pitolisant-for-treatment-of-cataplexy-in-adults-with-narcolepsy/2469405/The Food and Drug Administration (FDA) approved pitolisant (Wakix; Harmony Biosciences Plymouth Meeting, PA)—treatment of cataplexy in adults with narcolepsy. Pitolisant is the first and only treatment not categorized as a controlled substance that is approved by the FDA for treating sympto